Spelling suggestions: "subject:"cisplatin."" "subject:"displatin.""
171 |
The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in HCCGeng, Wei, 耿瑋 January 2009 (has links)
published_or_final_version / Surgery / Master / Master of Philosophy
|
172 |
Effects of Binding Affinity between Bovine Serum Albumin and Platinum DrugsPuckett, Nathan 01 April 2017 (has links)
Platinum complex drugs such as cisplatin have been used as highly successful chemotherapy drugs since the 1970s. We are interested in how the ligands attached to cisplatin analogs influences their reactivity with biologically relevant targets along with time and amount. For this study, reactions were conducted to determine the reactivity between different platinum compounds and the protein bovine serum albumin. Various platinum compounds with different ligands were reacted in varying amounts with albumin in ammonium acetate buffer for either 1 hour, 4 hours, or 24 hours. Each reaction was quenched after the designated reaction time by dialysis and the platinum bound to the protein was determined by use of ICP. LC-MS was used to find exact peptide residues platinum complexes prefer to bind with but was found to be ineffective. Results show that time has a more significant affect on binding over amount of platinum present. In respect to changing the leaving or carrier ligands on the platinum complex, these changes on the complex did not affect binding significantly with bovine serum albumin. Triamine platinum complexes also seem to bind significantly more than diamine platinum complexes along with anionic form platinum complexes binding significantly better than the cationic form platinum complexes.
|
173 |
Synergistic growth inhibition and enhancement of cell death by combination of Melanoma Differentiation Associated gene-7 (MDA-7/IL-24) and cisplatin in ovarian cancer cell linesLiu, Renyan 10 July 2009 (has links)
Ovarian cancer is the most lethal gynecological malignancy among women. The current first-line treatments for ovarian cancer are cisplatin, carboplatin and paclitaxel. However, resistance to these platinum-based drugs occurs in the large majority of initially responsive tumors, resulting in fully chemoresistant, fatal disease. Therefore, the resistance to cisplatin therapy has been a critical hurdle in the management of recurrent ovarian cancer. The mechanisms responsible for cisplatin resistance are not completely understood. In the search for new therapies to overcome/bypass cisplatin resistance, melanoma differentiation gene-7 (MDA-7) IL-24, which is a new cytokine, has anti-cancer efficacy by suppressing cell growth and inducing apoptosis in a broad range of tumor cells and does not induce any toxicity in normal cells, thus, making it a potentially effective therapeutic gene for ovarian cancer. The purpose of this study was to evaluate the potential therapeutic efficacy of MDA-7 to treat ovarian carcinoma. Since adenoviral-mediated MDA-7 gene therapy has been shown to be well tolerated and showed biological activity in clinical studies in the context of other carcinomas we assessed the anticancer effects of Ad.mda-7 and in combination with cis-platinum on ovarian cancer cells. Our results show that the purified recombinant MDA-7 protein, GST-MDA-7, and Ad.mda7 virus (5) induced growth arresst and apoptosis in ovarian cancer cells. However, the apoptosis induction was low and directly correlated with infectivity of Ad.mda-7 virus (5). The use of a modified Ad.mda-7 virus type5, Ad.mda-7 virus type(5/3), inhanced infectivity and significantly enhanced ovarian cancer cell killing in human ovarian cancer cell lines in vitro compared to unmodified Ad.mda-7 virus, Ad.mda-7 virus type5. Also Ad-mda7 synergizes with cis-platinum in vitro and enhances ovarian cancer cell death. Taken together, these findings demonstrate that MDA-7 is capable of promoting growth suppression and inducing cell death in ovarian cancer cells, at least OVCAR cells and support the pharmacological interest of the combination of MDA-7 and cis-platinum.
|
174 |
Platinum Complexes and Zinc Finger Proteins: From Target Recognition to FixationTsotsoros, Samantha 01 January 2014 (has links)
Bioinorganic chemistry strives to understand the roles of metals in biological systems, whether in the form of naturally occurring or addition of non-essential metals to natural systems. Metal ions play vital roles in many cellular functions such as gene expression/regulation and DNA transcription and repair. The study of metal-protein-DNA/RNA interactions has been relatively unexplored. It is important to understand the role of metalloprotein interactions with DNA/RNA as this enhanced knowledge may lead to better understanding of diseases and therefore more effective treatments. A major milestone in the development of this field was the discovery of the cytotoxic properties of cisplatin in 1965 and its FDA approval in 1978. Since then, two other chemotherapeutic drugs containing platinum, carboplatin and oxaliplatin, have been used in the clinic. These three compounds are all bifunctional with the ligands surrounding platinum In the cis conformation and rearrangement of the ligands to the trans orientation results in a loss of cytotoxic properties due to rapid deactivation through binding to S-containing proteins. This enhanced reactivity yields new opportunities to study the reactions between proteins and DNA. One of the first crosslinking experiments used transplatin to crosslink NCp7 to viral RNA in order to understand how/where the protein bound to RNA. We have studied the interaction between cis and trans dinuclear platinum complexes and the C-terminal zinc finger (ZF). The trans complex reacts at a faster rate than the cis isomer and causes N- terminal specific cleavage of the ZF. The dinuclear structure plays a critical role in the peptide cleavage as studies with transplatin (the mononuclear derivative) does not result in cleavage. Monofunctional trans platinum-nucleobase complexes (MPNs) serve as a model for the binding of transplatin to DNA. This provides an interesting opportunity to study their reactions with S-containing proteins, such as HIV1 NCp7. MPNs have been shown to bind to the C-terminal ZF of HIV1 NCp7, resulting in zinc ejection. This occurs through a two-step process where the nucleobase π-stacks with Trp37 on the ZF, followed by covalent binding at the labile Cl site to Cys. MPNs have also shown antiviral activity in vitro. The labile Cl on MPNs reduces specificity of these compounds, as it leaves an available coordination site on the platinum center for binding to other S-proteins or DNA. Therefore, we have moved to an inert PtN4 coordination sphere, [Pt(dien)L]2+ (dien= diethylenetri- amine). Due to the strong bond between platinum and nitrogen, covalent reactions are highly unlikely to occur at rapid rates. The strength of the pi-stacking interaction between nucleobases (free and platinated) and the aromatic amino acid, tryptophan (Trp), showed an enhanced binding constant for platinated nucleobases. This was confirmed by density functional theory (DFT) calculations as the difference in energy between the HOMO of Trp and the LUMO of the nucleobase was smaller for the platinum complex. The studies were extended to the Trp-containing C-terminal ZF of HIV1 NCp7 and an increase in association constant was seen compared to free Trp. Reaction of PtN4 nucleobases compounds with a short amino acid sequence con- taining either Ala (no pi-stacking capabilities) or Trp (pi-stacking interactions) revealed an enhanced rate of reactivity for the Trp-containing peptide. This result supports the theory of a two-step reaction mechanism where the platinum-nucleobase complex recognizes the pep- tide through a pi-stacking interaction with Trp followed by covalent binding to the platinum center. The [Pt(dien)L]2+ motif allows for systematic modification of the structural elements surrounding platinum in a search for the most effective compound. Methylation of the dien ligand should, in theory, increase lipophilicity of the compounds, however, due to 2+ charge of the compounds, this simple association does not hold true. Analysis of the cellular accumulation profiles showed little change in the uptake with the addition of methyl groups to the dien ligand, in agreement with the non-linear change in lipophilicity. Modification of L using different nucleobases allows for the tuning of the strength of the π-stacking interaction between Trp and the platinum complex. The addition of inosine (which lacks a H-bonding donor/acceptor at the C2 position) resulted in a lower association constant with both N-AcTrp and the C-terminal zinc finger of HIV1 NCp7. Interestingly, the addition of xanthosine resulted in an ehanced pi-stacking interaction with the C-terminal zinc finger of HIV1 NCp7; likely as a results of the addition of a H-bonding donor (double-bonded O) at the C2 position. The ability of PtN4 nucleobase complexes to inhibit formation of the NCp7 complexation with viral RNA was studied by mass spectrometry and gel electrophoresis. Dissociation of the NCp7-RNA complex was seen upon addition of PtN4 compounds. These compounds were also able to retard formation of the NCp7-RNA complex when pre-incubated with the protein. These results have important implications as inhibition of complex formation between NCp7 and viral RNA has negative implications for viral replication. Despite the success of platinum-nucleobase compounds, it is important to evaluate all potential pi-stacking ligands. A series of pyridine- and thiazole-based compounds were evaluated for the strength of the pi-stacking interaction with N-AcTrp and the C-terminal ZF of HIV1 NCp7. There was notable increase in association constant for the platinum- DMAP (4-dimethylaminopyridine) complex compared to other ligands studied. This result highlights the importance of exploring multiple avenues for the design of specifically targeted inhibitors and further confirms the viability of the medicinal chemistry dual approach of target recognition (non-covalent) followed by target fixation (covalent).
|
175 |
Effets des dommages de l'ADN et du stress oxydant sur la dégénérescence des structures neuroépithéliales de la cochlée lors de l'intoxication au cisplatine et au cours du vieillissement. / Effect of DNA damage and oxidative stress cochlear neuroepithelial structures degeneration after cisplatin poisening and during aging.Menardo, Julien 04 June 2013 (has links)
Dans nos sociétés modernes, la presbyacousie, perte de l'audition liée au vieillissement, prend une place de plus en plus importante. Outre le vieillissement de la population, la prévalence de la presbyacousie est accentuée par l'exposition à des bruits toujours plus forts (concerts, baladeurs, environnement de travail, ...) et la prise de médicaments ototoxiques (cisplatine, aminoglycosides, ...). À ce jour, le lien entre l'endommagement de l'ADN, le stress oxydant et l'inflammation avec l'apparition précoce de certaines maladies liées au vieillissement (Alzheimer, démence, Parkinson, …) a été démontré. Cependant, il n'existe aucune donnée concernant le rôle des dommages de l'ADN dans la dégénérescence des cellules cochléaires et trop peu d'études témoignent de l'existence d'un stress oxydant dans la presbyacousie.Le premier objet de ce travail a donc été d'élucider le rôle des dommages de l'ADN dans la dégénérescence des cellules cochléaires. Pour ce faire, nous avons utilisé des approches de biologie moléculaire et cellulaire pour identifier des voies de signalisation associées aux lésions de l'ADN dans des explants cochléaires issus de souris âgées de 3 jours traités au cisplatine (CDDP). Cet antinéoplasique tire sa cytotoxicité de sa capacité à causer directement des dommages dans l'ADN et est connu pour ses effets nocifs sur l'audition en induisant la dégénérescence des cellules cochléaires. Enfin, nous avons étudié l'implication de p53, un des effecteurs clés de signalisation des dommages de l'ADN, in vivo en traitant avec le CDDP des souris dont le gène codant pour ce facteur de transcription a été invalidé. Nos résultats montrent que le CDDP induit des cassures double brin dans l'ADN des cellules ciliées qui sont à l'origine de l'activation de la voie ATM/DNA¬PK-Chk2-p53, de la formation de foyers βH2AX et 53BP1 et, in fine, de la mort de ces cellules par apoptose. Les cellules ciliées internes, plus résistantes au CDDP que les cellules ciliées externes, présentent une signalisation moins intense et un nombre inférieur de cassures double brin, un phénomène qui pourrait expliquer leur plus faible sensibilité. Nous avons également montré que l'absence de p53 in vivo prévient les pertes d'audition et la dégénérescence des cellules ciliées externes après injection intrapéritonéale de CDDP. Le second objectif a porté sur l'étude des effets délétères du vieillissement sur l'audition et les mécanismes moléculaires associés à cette pathologie. Pour ce faire, nous avons choisi les souris SAMP8 (senescence accelerated mice prone 8), un modèle bien établi de sénescence précoce et des maladies liées au vieillissement. Nous avons combiné des approches fonctionnelles, morphologiques, moléculaires et cellulaires pour phénotyper ces souris et identifier l'origine de l'atteinte de leur audition au cours du vieillissement. L'étude des souris SAMP8 nous a permis de montrer qu'elles sont un excellent modèle de presbyacousie mixte (atteinte de la strie vasculaire, de l'organe de Corti et du ganglion spiral), résumant la pathologie humaine. La dégénérescence des structures cochléaires que nous avons observée chez ces souris provient d'une profonde dysfonction mitochondriale, de l'augmentation du stress oxydant et des processus inflammatoires, d'un stress autophagique et de l'endommagement de l'ADN. Les mécanismes moléculaires aboutissant à la perte des cellules cochléaires constituent autant de cibles thérapeutiques à explorer dans l'avenir afin de tenter de prévenir les troubles de l'audition imputables à l'exposition au bruit ou aux médicaments ototoxiques et au vieillissement. / Our modern society is confronted with a dramatic increase in the number of patients suffering from presbycusis or age related hearing loss. Besides aging, presbycusis prevalence increases with exposition to loud noise (concerts, Walkman, work environment …) and ototoxic drugs (cisplatin, aminoglycosides …). It was reported that the early onset of some aging related diseases (Alzheimer, dementia, Parkinson …) are linked mechanistically to DNA damage, oxidative stress and inflammation. However, the role of DNA damages in cochlear cells degeneration is totally unknown and only few studies have investigated the implication of oxidative stress in presbycusis.The first goal of this study consisted in clarifying the role of DNA damage in cochlear cell degeneration. For this purpose, we used molecular and cellular biology approaches to identify the activation of DNA damage response pathways in cisplatin (CDDP) treated 3 days postnatal mouse cochlear explants in culture. Indeed, the cytotoxicity of CDDP arises from its capacity to directly damage DNA. It is also well known that one of the major dose limiting side effects of CDDP is its ototoxicity. Finally, we investigated the role of p53, a key effector of the DNA damage response pathway, in vivo by treating p53 knockout mice with CDDP. Our results show that CDDP induces double strand breaks leading to the activation of ATM-/DNA PK¬ Chk2 p53 pathway, βH2AX and 53BP1 foci formation and, in fine, apoptotic cell death. Inner hair cells, which are more resistant to CDDP treatment than outer hair cells, show a less intense signaling and fewer double strand breaks. This phenomenon could explain their weaker sensitivity to CDDP treatment. In vivo, p53 deletion prevents hearing loss and outer hair cells degeneration induced bay intraperitoneal injection of CDDP.The second goal consisted in studying the deleterious effects of aging on hearing and the molecular mechanisms involved in this pathology. Here, we studied the mechanism of presbycusis using the senescence-accelerated mouse prone 8 (SAMP8) which is a useful model to probe the effects of aging on biological processes. Based on complementary approaches combining functional, morphological, biochemistry, cellular and molecular biology, we found that the SAMP8 strain displays premature hearing loss and cochlear degeneration recapitulating the processes observed in human presbycusis (i.e. strial, sensory and neural degeneration). The molecular mechanisms associated with premature presbycusis in SAMP8 mice involve oxidative stress, mitochondrial dysfunction, chronic inflammation, autophagic stress and DNA damages. Molecular mechanisms leading to cochlear cells loss represent therapeutic targets of interest to explore in the future in order to prevent hearing impairments due to loud sound or ototoxic drugs exposure and due to aging.
|
176 |
Avaliação da expressão dos genes homeobox em células de carcinoma mucoepidermoide tratadas com cisplatina / Evaluation of homeobox gene expression in cisplatin-treated mucoepidermoid carcinoma cellsCordeiro, Robson dos Santos 21 February 2019 (has links)
O carcinoma mucoepidermoide (CME) é a neoplasia maligna de glândula salivar mais comum, e com maior frequência de metástase linfonodal. Alterações genéticas estão intimamente associadas à carcinogênese e, também, aos processos de metástase tumoral. Para o CME o tratamento de escolha mais aplicado hoje é a cirurgia seguida de radioterapia, pois a quimioterapia não tem mostrado muita eficiência para o tratamento destas neoplasias. Entre os quimioterápicos mais prescritos para o tratamento de cânceres encontra-se a cisplatina, à base de platina, que atua no DNA da célula, induzindo a apoptose. Pouco se sabe a respeito de seu mecanismo de ação sobre o CME, inclusive sobre os genes homeobox. Estes genes compreendem uma família grande e essencial de reguladores do desenvolvimento que são vitais para o crescimento e diferenciação celular, e a expressão anômala destes genes têm sido implicados na carcinogênese. Assim, este trabalho teve como objetivo avaliar a expressão dos genes homeobox em células derivadas de carcinoma mucoepidermoide tratadas com cisplatina. Os genes avaliados neste trabalho foram: PROX1, MEIS1, HOXB5, HOXB7 e HOXB9 por RT-qPCR. Previamente, as linhagens celulares derivadas de carcinoma mucoepidermoide UM-HMC1 UM-HMC2 e UM-HMC3A foram tratadas com a cisplatina por 24h e posteriormente submetidas aos ensaios de RT-qPCR. Adicionalmente, as amostras tratadas e sem tratamento foram analisadas pelo ensaio de formação de esferas e ensaio de ferida para verificar o efeito da cisplatina sobre propriedades relacionadas às células quimiorresistentes (putativas células tronco tumorais). Como resultados, entre os genes analisados foram expressos PROX1, MEIS1 e HOXB7. A UM-HMC3A apresentou maior expressão destes genes que as demais linhagens. Os genes HOXB5 e HOXB9 não foram expressos nas linhagens analisadas. A cisplatina reduziu a expressão de MEIS1 e aumentou a expressão de HOXB7, em todas as linhagens. O gene PROX1 apresentou expressão variável entre as linhagens, sendo expresso na UM-HMC1 apenas quando são tratadas com cisplatina e reduzido nas UM-HMC2 e UM-HMC3A tratadas. O número de esferas formadas não apresentou diferença significativa para UM-HMC1 e UM-HMC3A, o número de esferas aumentou na linhagem UM-HMC2 tratada com cisplatina. No ensaio de ferida, a cisplatina foi capaz de reduzir a migração celular em todas as linhagens quando comparadas com seus controles. Os resultados sugerem que o PROX1 e HOXB7 podem estar relacionados com carcinomas mucoepidermoides mais invasivos, enquanto que o MEIS1 pode estar relacionado à carcinogênese e autorrenovação tumoral. A cisplatina é capaz de afetar a expressão dos genes homeobox PROX1, MEIS1 e HOXB7, os quais foram encontrados nas linhagens de carcinoma mucoepidermoide analisados. A cisplatina não afeta as células formadoras de esferas, mas reduzir a migração das linhagens de carcinoma mucoepidermoide. / Mucoepidermoid carcinoma (MEC) is the most common malignant neoplasm of salivary gland and presents higher frequency of lymph node metastasis. Genetic alterations are closely associated with carcinogenesis and also with processes of tumor metastasis. For MEC the treatment of choice most applied today is surgery followed by radiotherapy, since chemotherapy has not shown much efficiency for the treatment of these neoplasms. Among the most commonly prescribed chemotherapic drugs for cancer treatment is platinum-based cisplatin, which acts on the cell\'s DNA, inducing apoptosis. There is no information in the literature regarding its action mechanism on MEC including homeobox genes. These genes comprise a large and essential family of developmental regulators that are vital for cell growth and differentiation and the anomalous expression of these genes have been implicated in carcinogenesis. Therefore, this work aimed to evaluate the expression of the homeobox genes in cells derived from mucoepidermoid carcinoma treated with cisplatin. The genes evaluated in this work were: PROX1, MEIS1, HOXB5, HOXB7 and HOXB9 by RT-qPCR. Previously, cell lines derived from mucoepidermoid carcinoma UM-HMC1 UM-HMC2 and UM-HMC3A were treated with cisplatin for 24h and subsequently subjected to the RT-qPCR assays. In addition, treated and untreated samples were analyzed by the sphere-forming assay and wound assay to verify the effect of cisplatin on chemo resistant cell-related (putative tumor stem cell) properties. As results, PROX1, MEIS1 and HOXB7 were expressed among the analyzed genes. UM-HMC3A showed higher expression of these genes than the other lineages. The HOXB5 and HOXB9 genes were not expressed in the analyzed lineages. Cisplatin reduced MEIS1 expression and increased HOXB7 expression in all lineages. The PROX1 gene showed variable expression between the lineages, being expressed in UM-HMC1 only when treated with cisplatin and reduced in treated UM-HMC2 and UM-HMC3A. The number of spheres formed did not show significant difference for UM-HMC1 and UM-HMC3A, the number of spheres increased in the cisplatin-treated UM-HMC2 lineage. In the wound assay, cisplatin was able to reduce cell migration in all lineages when compared to their controls. The results suggested that PROX1 and HOXB7 may be related to more invasive mucoepidermoid carcinoma, while MEIS1 be related to its carcinogenesis and selfrenew tumoral capacity. Cisplatin is capable to affect the expression of the homeobox genes PROX1, MEIS1 and HOXB7, which were found in the mucoepidermoid carcinoma cell lines analyzed. Cisplatin does not affect sphere formation of cells, but seems to reduce the migration of mucoepidermoid carcinoma lineages.
|
177 |
[en] THE 6-AMINOPURINE STUDY AND ITS PLATINUM (III) COMPLEXES AS LEISHMANICIDS POTENTIALS / [pt] ESTUDO DE 6-AMINOPURINAS E SEUS COMPLEXOS DE PLATINA (II) COMO POTENCIAIS LEISHMANICIDASDENISE OLIVEIRA DA ROSA 25 September 2007 (has links)
[pt] A cisplatina é um quimioterápico amplamente utilizado no
tratamento de
uma grande variedade de tumores sólidos. Porém, o
desenvolvimento de
resistência a este fármaco e os severos efeitos
colaterais, como nefrotoxicidade
têm sido grandes obstáculos para um tratamento mais
eficaz. A cisplatina é
também usada no tratamento da leishmaniose. Neste trabalho
desenvolveu-se
uma metodologia para sintetizar análogos da cisplatina com
ligantes derivados de
aminopurinas, visando obter um produto com atividade
leihmanicicida mas que
apresente menor toxicidade. Foram feitos estudos para
chegar à melhor rota
sintética de obtenção dos ligantes e complexos
representadas. A síntese do
ligante consiste em duas etapas, a primeira envolve a
oxidação da 6-
metilmercaptopurina até 6-metilsulfonilpurina, a segunda
etapa leva a obtenção
das respectivas 6-aminopurinas. Nesta segunda etapa foi
feito um estudo
relacionado ao caráter nucleofílico das aminas aromáticas.
Na etapa de formação
do complexo, isto é na interação entre as 6-aminopurinas e
cisplatina foram
analisados alguns parâmetros como temperatura, tempo de
reação, pH e
solubilidade no solvente. A escolha das 6-aminopurinas
como ligantes foi
fundamental, pois na literatura1.7 é citado a grande
atividade biológica desses
compostos e os protozoário da leishmania necessitam de
purina do meio para
sobreviver. Todas as substâncias sintetizadas foram
caracterizadas através das
seguintes técnicas, CHN, TGA, IV, RMN-1H, RMN-13C e
espectrometria de massa
(LDI). Os testes biológicos efetuados demostram que alguns
compostos têm
atividade leishmanicida. / [en] Cisplatin is a widely used chemotherapeutic drug in the
treatment of
several solid tumors. However, the resistance developed to
the drug together
with its severe side effects, such as nephrotoxicity, have
been obstacles to a
more efficient treatment. Cisplatin is also used in the
treatment of leishmaniose.
In this study, a methodology was developed to synthesize
cisplatin with ligands
derived from aminopurines, with the aim of obtaining
products with antineoplasic
potential and biological activity, but presenting a
reduction of its toxicity. The
synthesis of the ligand consists of two stages, the first
involves the oxidation of
the 6-methylmercaptopurine to 6-methylsulphonilpurine and
is followed by the
aminolysis of the latter to respective 6-aminopurines. In
this second stage a
study was made of the nucleofilic character of these
aromatic amines. In the
complex formation stage, that is, in the interaction
between the 6-aminopurines
and cisplatin, parameters such as temperature, time of
reaction, pH and solvent
solubility were analyzed. The relationship between the
group in the position 6 of
these 6-aminopurines and their reactivity with cisplatin
was also studied. The
choice of 6-aminopurines as ligants was fundamental, the
literature1.7 shows a
huge biological activity of these composts and the
leishmania protozoary needs
the purine media to survine. All synthesized substances
were characterized using
the following techniques: CHN, TGA, IR, NMR-1H, NMR-13C
and Mass
Spectrometry (LDI). Biological activity testes showed that
one of the compounds
has leishmanicide
|
178 |
[en] DETERMINATION OF PLATINUM DERIVED FROM ANTI-CANCER DRUGS IN URINE SAMPLES BY ATOMIC ABSORPTION SPECTROMETRY / [pt] DETERMINAÇÃO DE PLATINA PROVENIENTE DE SUBSTÂNCIAS ANTINEOPLÁSICAS EM URINA POR GF AAS E HR-CS F AASANILTON COELHO COSTA JUNIOR 11 December 2007 (has links)
[pt] Devido à sua capacidade de inibição do processo de divisão
celular,
complexos de platina têm sido empregados na quimioterapia
do câncer desde o
final da década de 60, sendo a cisplatina e a carboplatina
as formas mais
utilizadas. Estudos farmacocinéticos e a estimativa da
quantidade de platina
acumulada no organismo durante o tratamento quimioterápico
ou devido à
exposição ao metal têm sido alvo de grande interesse.
Logo, são necessários
métodos analíticos adequados para o monitoramento de
platina em amostras
clínicas, apropriados para essas diferentes substâncias.
No presente trabalho,
foram desenvolvidos procedimentos analíticos rápidos,
simples e exatos para
determinação direta de platina, na forma de cisplatina e
carboplatina, em urina
humana, utilizando a espectrometria atômica. No caso da
absorção atômica em
forno de grafite, o programa de temperatura, o volume de
amostra e a
concentração do diluente (HNO3) foram definidos por um
planejamento
composto central. Nas condições otimizadas, os resultados
obtidos pelo
procedimento proposto não apresentaram diferenças
estatisticamente
significativas daqueles obtidos por procedimentos
comparativos independentes,
na análise de amostras de urina de paciente submetido ao
tratamento com
cisplatina. A calibração foi realizada por adição de
analito, com PtCl2. Com a
adição de NaCl ao meio diluente, os efeitos
multiplicativos de matriz puderam ser
contornados, permitindo a calibração externa com soluções
de calibração
preparadas no mesmo meio que o branco, utilizando sais
inorgânicos de platina.
Melhor sensibilidade também foi obtida, e recuperações de
98±4% foram
observadas para os vários níveis de concentração
estudados, assim como
coeficientes de variação de 1 a 10%, tanto para a cis como
para a carboplatina.
O limite de detecção (n=10, k=3) foi de 4 (mi)g L-1 de Pt
na amostra original. A
espectrometria de absorção atômica com fonte contínua de
alta resolução na
chama (HR-CS F AAS) também foi estudada. As condições da
chama foram
definidas por um planejamento multivariado D-optimal,
tomando-se como
resposta a soma dos coeficientes angulares das curvas de
adição de analito em
três urinas diferentes, assim como o desvio padrão
relativo dessas inclinações.
O limite de detecção foi de 55 Og L-1 (n=10, k=3), na
amostra original, em Pt,
cerca de uma ordem de grandeza melhor do que aquele obtido
utilizando-se um equipamento de fonte de linhas.
Calibração externa, com soluções de calibração
em urina livre de Pt, utilizando sal inorgânico de platina
(PtCl2), foi possível, e os
resultados obtidos por HR-CS F AAS não se mostraram
significativamente
diferentes daqueles encontrados por procedimentos
comparativos
independentes. / [en] Platinum coordination compounds have been used in cancer
chemotherapy
since the late 1960s. Cisplatin and carboplatin are the
most common platinum
based drugs used in cancer treatment. Pharmacokinetics
investigations, the
determination of the body burden during the treatment as
well as the baseline
levels of platinum in humans has attracted great interest.
Thus, accurate
analytical methods for fast and easy platinum monitoring
in clinical samples are
necessary. In the present work, atomic spectrometric
methods for the direct
determination of platinum as cisplatin and carboplatin in
human urine were
investigated. In relation to Graphite Furnace Atomic
Absorption Spectrometry the
optimum temperature program, sample volume and diluent
concentration were
defined by a central composite design optimization.
Analyte addition with PtCl2
was used for calibration, and no statistically significant
difference was observed
between the results obtained by the proposed and
comparative procedures in the
analysis of a set of urine samples. Multiplicative matrix
effects were overcome by
adding NaCl to the diluent solution. External calibration
with PtCl2 in blank
matched medium was then possible. The recoveries were
100±1%, and the
coefficient of variation ranged from 1 to 10%. The limit
of detection (LOD) was 4
ug L-1 of Pt in the original urine sample. High resolution
continuous source flame
atomic absorption spectrometry was also investigated. The
flame conditions were
optimized by a multivariate D-optimal design, taking as
response the sum of the
analyte addition calibration slopes and their standard
deviation. The LOD was 55
Og L-1 (n=10, k=3), in the original sample. Matrix matched
external calibration with
PtCl2, was possible, and the results obtained by the
proposed procedure were
also in good agreement with those obtained by independent
comparative
procedures.
|
179 |
[en] SYNTHESIS AND CHARACTERIZATION OF RESULTANT COMPOUNDS FROM THE INTERACTION OF CISPLATINUM WITH GUANIDINOACETIC ACID AND ARGININE / [pt] SÍNTESE E CARACTERIZAÇÃO DE COMPOSTOS RESULTANTES DA INTERAÇÃO DE CISPLATINA COM ÁCIDO GUANIDOACÉTICO E ARGININALUCIANA DORNELAS PINTO 30 October 2006 (has links)
[pt] Este trabalho teve como objetivo o estudo das interações
entre a cisplatina,
que é usada como medicamento quimioterápico e dois
aminoácidos de
importância biológica: ácido guanidoacético (Gaa) e
arginina (Arg). Por esta
razão, procurou-se trabalhar in vitro com condições
próximas ao meio biológico
utilizando, em função disto, apenas água deionizada como
solvente. Para isto,
foram testados vários procedimentos de síntese que
resultaram em quatro
compostos diferentes: dois com o Gaa e dois com a
arginina. Estes compostos
foram caracterizados pelas seguintes técnicas: análise
elementar (espectrometria
de absorção atômica e CHN), condutimetria, análise
termogravimétrica,
ressonância magnética nuclear, difração de pó e
espectroscopia de infravermelho.
Foi possível verificar que tanto o Gaa como a arginina
comportam-se como
monodentados e complexam-se com a cisplatina através do
átomo de nitrogênio
da amina. / [en] The aim of this work is the study of the interactions
between cis-platinum,
which is employed as a chemotherapic drug, and two amino
acids of biological
importance: guanidinoacetic acid (Gaa) and arginine (Arg).
In order to work in
conditions as similar as possible of the biological
environment, this work was
done in vitro, using only deionized water as a solvent.
With this purpose, several
synthesis procedures were tested which resulted in four
different compounds: two
with Gaa and two with arginine. These compounds were
characterized through
the following techniques: elementary analysis (atomic
absorption spectrometry
and CHN), conductimetry, thermogravimetric analysis,
nuclear magnetic
resonance, powder diffraction and infrared spectroscopy.
It was possible to verify
that both Gaa and arginine behaved as monodentates ligands
and complexed with
the cis-platinum through the amine´s nitrogen atom.
|
180 |
Avaliação da morte celular induzida pela associação de paclitaxel e cisplatina em linhagens celulares derivadas de tumor de cabeça e pescoço. / Evaluation of cell death induced by the combination of paclitaxel and cisplatin in cell lines derived from head and neck squamous cell carcinoma.Victo, Nathália Cruz de 02 September 2013 (has links)
Os tumores de cabeça e pescoço ocupam o sexto lugar no ranking de incidência mundial, e estão localizados na região da face, fossas nasais, seios paranasais, boca, faringe, laringe entre outros tecidos moles do pescoço. O tabagismo, o etilismo, a radiação solar e o vírus HPV, são fatores de risco associados a esse tipo de tumors. A terapia combinada de drogas antineoplásicas tem sido utilizada para amenizar os efeitos colaterais e potencializar o tratamento antitumoral. A combinação de paclitaxel e cisplatina tem se mostrado eficaz em tumores sólidos, como o HNSCC. A morte celular induzida pelo paclitaxel é mediada pela ruptura da dinâmica dos microtúbulos normais, já a cisplatina induz ligações cruzadas de DNA estes tratamentos induzem a célula à morte por apoptose. A apoptose é um processo de morte dividido, didaticamente, em via intrínseca (via mitocondrial) e via extrínseca (via receptor de morte). Entender por qual via essas células tumorais são induzidas a morte é fundamental para tentar evitar a resistência dessas células ao tratamento. Nosso objetivo é entender se células tumorais de HNSCC são resistentes ou sensíveis ao tratamento com paclitaxel e cisplatina sozinhos ou em associação. Para isso, realizamos o tratamento da linhagem celular FaDu por um período de 48 horas com as drogas e verificamos sua resistência a indução de morte por esses tratamentos. Os resultados mostraram que o tratamento com paclitaxel não potencializa a morte desta célula, sendo a linhagem FaDu mais sensível ao tratamento com cisplatina e a associação apresenta o mesmo perfil de quando tratada com cisplatina. A morte desta linhagem é dependente de caspases e possui uma preferência pela via extrínseca da apoptose que, consequentemente, induz a morte também pela via intrínseca. A modulação desta morte se dá pelo balanço das proteínas pró- e anti-apoptóticas da família BCL-2 que são responsáveis pela regulação da apoptose, o tratamento com cisplatina induz a expressão da proteína pró-apoptótica BAK e a diminuição das proteínas anti-apoptóticas BCL-2 e BCL-XL. Com os resultados obtidos, concluímos que a associação de paclitaxel e cisplatina não potencializa a morte da linhagem celular FaDu. Contudo, a cisplatina apresentou-se efetiva na indução de morte por apoptose através do aumento da expressão da proteína BAK e a diminuição da expressão das proteínas BCL-2 e BCL-XL. / Head and neck squamous cell carcinoma is the sixth most common cancer in the world, and are located in the region of the face, nasal fossas, sinuses, mouth, pharynx, larynx and other soft tissues of the neck. Tobacco smoke, etilism, solar radiation and HPV are risk factors associated with this type of tumors. Combination therapy of anticancer drugs has been used to alleviate the side effects and potentiate the antitumor treatment. The combination of paclitaxel and cisplatin has been shown to be effective in solid tumors such as HNSCC. The paclitaxel-induced cell death is mediated by disruption of the normal microtubule dynamics, and the cisplatin induced DNA cross-links, these treatments induce cell death by apoptosis. Apoptosis is a death process divided in, intrinsic pathway (mitochondrial pathway) and extrinsic pathway (death receptor pathway). Understand by what pathway those tumor cells which are induced death is important to try and avoid the resistance of these cells to treatment. Our aims understand if HNSCC tumor cells are resistant or sensitive to treatment with paclitaxel and cisplatin alone or in combination. We carried out the treatment of cell line FADU a period of 48 hours with the drug and we verify their resistance to death induction by these treatments. The results showed that treatment with paclitaxel did not potentiate the cell death, in the other hand, FADU cell line appeared to be more sensitive to cisplatin treatment, and the association has the same profile when treated with cisplatin. The death of this line is dependent on caspases and has a preference for the extrinsic pathway of apoptosis, consequently, also induces the death by the intrinsic pathway. The modulation of death is caused by the balance of pro-and anti-apoptotic proteins of BCL-2 family proteins that are responsible for regulation of apoptosis, treatment with cisplatin induces the expression of pro-apoptotic protein BAK and the decrease of anti-apoptotic proteins BCL -2 and BCL-XL. With these results, we conclude that the combination of paclitaxel and cisplatin did not potentiate the cell death of the cell line Fadu. However, cisplatin showed to be effective in induction of death by apoptosis through increased expression of BAK protein and decreased expression of BCL-2 and BCL-XL.
|
Page generated in 0.0473 seconds